Study of PROSPECT IV (Prostamol: Perspectives of Combined Therapy) in Patients with Benign Prostatic Hyperplasia

The study aimed to evaluate the efficacy and safety of a nine-year combination therapy of "Flosin – Prostamol Uno" in patients with benign prostatic hyperplasia (BPH). Out of 94 patients from the previous PROSPECT III study, 37 were followed up for nine years. The study compared two groups: 33 patients received "Flosin – Prostamol Uno," and 4 received "doxazosin – finasteride." Results showed that "Flosin – Prostamol Uno" had high therapeutic efficacy and was well tolerated, with a lower incidence of adverse events (5.75%) compared to the control group (27%). The level of acute urinary retention in the treatment group was 19%. The study concluded that patient adherence to the "Flosin – Prostamol Uno" therapy was high, and it effectively managed BPH symptoms over the long term.